Amil M. Shah

Active 2003–2026

169
Papers
20,903
Citations
79
h-index
153
i10-index

Citations

Citations per year for Amil M. Shah1970: 1 citations1996: 6 citations2003: 1 citations2004: 1 citations2005: 3 citations2007: 5 citations2008: 5 citations2009: 4 citations2010: 8 citations2011: 20 citations2012: 28 citations2013: 57 citations2014: 82 citations2015: 124 citations2016: 171 citations2017: 146 citations2018: 169 citations2019: 797 citations2020: 1,031 citations2021: 1,044 citations2022: 943 citations2023: 636 citations2024: 1,145 citations2025: 657 citations2026: 23 citations1971–1995: no citations, so these years are not shown1997–2002: no citations, so these years are not shown2006: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,594 citing papers, 23.2% of this breakdownItaly: 806 citing papers, 7.2% of this breakdownUnited Kingdom: 804 citing papers, 7.2% of this breakdownChina: 737 citing papers, 6.6% of this breakdownGermany: 619 citing papers, 5.6% of this breakdownNetherlands: 429 citing papers, 3.9% of this breakdownCanada: 421 citing papers, 3.8% of this breakdownFrance: 362 citing papers, 3.2% of this breakdownJapan: 355 citing papers, 3.2% of this breakdownAustralia: 306 citing papers, 2.7% of this breakdownSpain: 289 citing papers, 2.6% of this breakdownSweden: 257 citing papers, 2.3% of this breakdown
0%23.2%Other 28.5%

Fields

  • Medicine78.2%
  • Biochemistry, Genetics and Molecular Biology17%
  • Immunology and Microbiology0.9%
  • Neuroscience0.8%
  • Engineering0.7%
  • Nursing0.5%
  • Other1.9%

Topics

  • Cardiovascular Function and Risk Factors13.5%
  • Heart Failure Treatment and Management8.3%
  • Cardiac Imaging and Diagnostics3.8%
  • Amyloidosis: Diagnosis, Treatment, Outcomes3.6%
  • Cardiac pacing and defibrillation studies2.4%
  • Atrial Fibrillation Management and Outcomes2%
  • Other66.4%

Coauthors

All papers

Open in search
  1. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Shiangtung W. Jung, Brenda F. Baker, Elizabeth J. Ackermann, Morie A. Gertz, Teresa Coelho - New England Journal of Medicine 2018 cited by 1,422

  2. Heart Failure With Preserved Ejection Fraction In Perspective

    Authors: , , - Circulation Research 2019 cited by 830

  3. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis

    Authors: , , , , , , , , , - The Lancet Public Health 2018 cited by 763

  4. Association of Clonal Hematopoiesis With Incident Heart Failure

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2021 cited by 215

  5. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction

    Authors: , , , , , , , , , , - European Heart Journal 2017 cited by 568

  6. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2019 cited by 370

  7. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis

    Authors: , , , , , , , , , , , , , , , , , , , - Circulation 2019 cited by 461

  8. Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction

    Authors: , , , , , , , , , , , - Journal of the American College of Cardiology 2013 cited by 755

  9. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction

    Authors: , , , , , , , , , , , , - JAMA 2019 cited by 624

  10. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

    Authors: , , , , , , , , , , , , - The Lancet 2012 cited by 1,169

  11. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction

    Authors: , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2019 cited by 254

  12. A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction

    Authors: , , , , , , , , , , , , , - JAMA Cardiology 2022 cited by 122

  13. Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction

    Authors: , , , , , , , , , , , , , , , - JAMA Network Open 2024 cited by 66

  14. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction

    Authors: , , , , , , , , , , - JAMA 2019 cited by 320

  15. Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study

    Authors: , , , , , , , , , , , , - European Journal of Preventive Cardiology 2023 cited by 65

  16. Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community

    Authors: , , , , , , , , - JACC Heart Failure 2020 cited by 139

  17. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction

    Authors: , , , , , , , , , , - Circulation Heart Failure 2016 cited by 324

  18. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone

    Authors: , , , , , , , , - Circulation 2015 cited by 477

  19. Global Longitudinal Strain by Echocardiography Predicts Long-Term Risk of Cardiovascular Morbidity and Mortality in a Low-Risk General Population

    Authors: , , , , , , , - Circulation Cardiovascular Imaging 2017 cited by 399

  20. Sex-Specific Cardiovascular Structure and Function in Heart Failure with Preserved Ejection Fraction

    Authors: , , , , , , , , , , , , , , , , - European Journal of Heart Failure 2014 cited by 238

  21. Heart Failure Stages Among Older Adults in the Community

    Authors: , , , , , , , , , , , , , , - Circulation 2016 cited by 196

  22. Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction

    Authors: , , , , , , , , - Journal of the American Heart Association 2017 cited by 165

  23. The Amyloidogenic V122I Transthyretin Variant in Elderly Black Americans

    Authors: , , , , , , , , , - New England Journal of Medicine 2014 cited by 257

  24. Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction

    Authors: , , , , , , , , , , , , , , - JACC Heart Failure 2019 cited by 123